These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8195453)

  • 1. Buspirone's efficacy in organic-induced aggression.
    Stanislav SW; Fabre T; Crismon ML; Childs A
    J Clin Psychopharmacol; 1994 Apr; 14(2):126-30. PubMed ID: 8195453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic management of aggression in the elderly.
    Yudofsky SC; Silver JM; Hales RE
    J Clin Psychiatry; 1990 Oct; 51 Suppl():22-8; discussion 29-32. PubMed ID: 1976621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study.
    Ratey J; Sovner R; Parks A; Rogentine K
    J Clin Psychiatry; 1991 Apr; 52(4):159-62. PubMed ID: 2016248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can aggressive behavior in humans be modified by beta blockers?
    Volavka J
    Postgrad Med; 1988 Feb; Spec No():163-8. PubMed ID: 2894657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons.
    Ratey JJ; Sovner R; Mikkelsen E; Chmielinski HE
    J Clin Psychiatry; 1989 Oct; 50(10):382-4. PubMed ID: 2793836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buspirone for autistic disorder in a woman with an intellectual disability.
    Brahm NC; Fast GA; Brown RC
    Ann Pharmacother; 2008 Jan; 42(1):131-7. PubMed ID: 18056831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study.
    Greendyke RM; Kanter DR
    J Clin Psychiatry; 1986 Aug; 47(8):423-6. PubMed ID: 3525523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pica: a descriptive study of patients in a speciality medical center].
    Haoui R; Gautie L; Puisset F
    Encephale; 2003; 29(5):415-24. PubMed ID: 14615690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of community-based individuals with mental retardation and aggressive behavioral disorders.
    Davidson PW; Cain NN; Sloane-Reeves JE; Van Speybroech A; Segel J; Gutkin J; Quijano LE; Kramer BM; Porter B; Shoham I
    Am J Ment Retard; 1994 May; 98(6):704-16. PubMed ID: 8054199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-aggressive effect of beta-blockers].
    Thibaut F; Colonna L
    Encephale; 1993; 19(3):263-7. PubMed ID: 7903928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
    Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
    Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes.
    Horne M; Lindley SE
    J Clin Psychiatry; 1995 Sep; 56(9):430-1. PubMed ID: 7665542
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of violent behavior among acute psychiatric patients: clinical study.
    Amore M; Menchetti M; Tonti C; Scarlatti F; Lundgren E; Esposito W; Berardi D
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):247-55. PubMed ID: 18588583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychiatric illness following traumatic brain injury in an adult health maintenance organization population.
    Fann JR; Burington B; Leonetti A; Jaffe K; Katon WJ; Thompson RS
    Arch Gen Psychiatry; 2004 Jan; 61(1):53-61. PubMed ID: 14706944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
    J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study.
    Verhoeven WM; Tuinier S
    J Intellect Disabil Res; 1996 Dec; 40 ( Pt 6)():502-8. PubMed ID: 9004110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buspirone for the treatment of dementia with behavioral disturbance.
    Santa Cruz MR; Hidalgo PC; Lee MS; Thomas CW; Holroyd S
    Int Psychogeriatr; 2017 May; 29(5):859-862. PubMed ID: 28124634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone in the treatment of posttraumatic stress disorder.
    Wells BG; Chu CC; Johnson R; Nasdahl C; Ayubi MA; Sewell E; Statham P
    Pharmacotherapy; 1991; 11(4):340-3. PubMed ID: 1923917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of buspirone on intractable self-injury in adults with mental retardation.
    Ricketts RW; Goza AB; Ellis CR; Singh YN; Chambers S; Singh NN; Cooke JC
    J Am Acad Child Adolesc Psychiatry; 1994 Feb; 33(2):270-6. PubMed ID: 8150800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.